JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease
Author:
Affiliation:
1. Department of Internal Medicine, “Villa Sofia-Cervello” Hospital, Palermo, Italy
2. IBD Unit, Gastroenterology Department, Hospital de Galdakao, Galdakao (Vizcaya), Spain
Abstract
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference62 articles.
1. Abraham C.; Cho J.H.; Inflammatory bowel disease. N Engl J Med 2009,361(21),2066-2078
2. Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology, 2015,,148((2),344.54 e5; quiz e14-5)
3. Lv R.; Qiao W.; Wu Z.; Wang Y.; Dai S.; Liu Q.; Zheng X.; Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One 2014,9(1)
4. Armuzzi A.; Gionchetti P.; Daperno M.; Danese S.; Orlando A.; Lia Scribano M.; Vecchi M.; Rizzello F.; Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group2016,48(4),360-370
5. Macaluso F.S.; Orlando A.; Cottone M.; Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opin Biol Ther 2019,19(2),89-98
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study;Digestive and Liver Disease;2024-01
2. Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies;Digestive and Liver Disease;2022-02
3. Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?;Gastroenterology;2021-04
4. New Therapeutic Molecules and their Metabolism in Gastroenterology;Current Drug Metabolism;2020-06-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3